D
Sell
12/14/2023Upgraded
NewAmsterdam Pharma Company N.V. (NAMS) was upgraded to D- from E+ on 12/14/2023 due to an increase in the volatility index.
E
Sell
11/29/2023Downgrade
NewAmsterdam Pharma Company N.V. (NAMS) was downgraded to E+ from D- on 11/29/2023 due to a decline in the volatility index and valuation index.
D
Sell
10/30/2023Upgraded
NewAmsterdam Pharma Company N.V. (NAMS) was upgraded to D- from E+ on 10/30/2023 due to an increase in the volatility index.
E
Sell
10/13/2023Downgrade
NewAmsterdam Pharma Company N.V. (NAMS) was downgraded to E+ from D- on 10/13/2023 due to a large decline in the volatility index and total return index.
D
Sell
8/17/2023Downgrade
NewAmsterdam Pharma Company N.V. (NAMS) was downgraded to D- from D on 8/17/2023 due to a significant decline in the valuation index, growth index and volatility index. Operating cash flow declined 1.5% from -$33.71M to -$34.21M, EBIT declined 1.5% from -$41.31M to -$41.93M, and earnings per share declined from -$0.4933 to -$0.5007.
D
Sell
7/5/2023Downgrade
NewAmsterdam Pharma Company N.V. (NAMS) was downgraded to D from B- on 7/5/2023 due to a significant decline in the efficiency index, volatility index and valuation index. Net income declined 1.4% from -$66.79M to -$67.72M.
B
Buy
3/20/2023Upgraded
NewAmsterdam Pharma Company N.V. (NAMS) was upgraded to B- from D on 3/20/2023 due to a large increase in the volatility index and total return index.
D
Sell
12/2/2022None
NewAmsterdam Pharma Company N.V. (NAMS) was downgraded to D from U on 12/02/2022.
